Bortezomib helps girl avoid liver transplant rejection, return of PFIC2
Bortezomib, an anticancer medication, prevented a recurrence of progressive familial intrahepatic cholestasis type 2 (PFIC2) after a liver transplant by helping a young girl…
News
Websites of transplant centers in US stigmatize ALD with word choice
Most liver transplant centers in the U.S. continue to use stigmatizing language on their websites that could make people with alcohol-associated liver disease (ALD)…
Livmarli eases itch for broader pediatric population with Alagille
Livmarli (maralixibat) safely and effectively eases itching caused by Alagille syndrome in children who would have been excluded from the clinical trials that…
GSK’s hepatitis B candidate bepirovirsen wins fast track status
The U.S. Food and Drug Administration (FDA) has granted fast track status to bepirovirsen, GlaxoSmithKline (GSK)’s candidate treatment for chronic hepatitis B (CHB),…
Bexotegrast shows positive signs as PSC treatment in Phase 2 trial
Pliant Therapeutics’ investigational oral treatment bexotegrast safely eases itching and is associated with signs of better liver function and less liver scarring, or fibrosis, in…
Protein’s levels in placenta may be key for diagnosing, treating ICP
Intrahepatic cholestasis of pregnancy (ICP), a liver disorder that can affect a pregnant woman, leads to abnormally high levels of a protein called ERp29…
Resmetirom successfully treats NASH, reduces liver scarring in trial
One year of daily resmetirom, Madrigal Pharmaceuticals’ investigational oral therapy, was shown to successfully treat nonalcoholic steatohepatitis (NASH), a severe type of fatty liver…
Bile acids stay high in biliary atresia patients after Kasai procedure
Bile acids, which aid the fat-digesting functions of bile fluid, remain elevated in the blood and urine of adult biliary atresia patients whose bile…
Canada funds projects to curb hepatitis C, blood-borne infections
Community-based organizations in Canada addressing hepatitis C, the human immunodeficiency virus (HIV), and other sexually transmitted and blood-borne infections (STBBIs) will receive more than…
FDA to review approval application for seladelpar as PBC treatment
The U.S. Food and Drug Administration (FDA) will review CymaBay Therapeutics’ application for seladelpar, an oral investigational treatment for adults with…
Recent Posts